Dosing and uses of Magnitria (trimagnesium citrate anhydrous)
Adult dosage forms and strengths
oral powder
- 1504mg/powder sachet (elemental magnesium/sachet: 243mg [20mEq])
Magnesium Supplementation
Dietary supplement to treat or reduce the risk of magnesium deficiency
Dose based on elemental magnesium (Mg) 243-486 mg PO daily
If 486 mg/day administered, give as 2 doses 4-8 hr apart
Dosing Considerations
Indication: Recommended to treat or reduce the risk of hypomagnesemia in individuals diagnosed with a cardiovascular condition (eg, congestive heart failure, hypertension, tachyarrhythmia, atherosclerosis); gastrointestinal condition (eg, Crohn’s disease, ulcerative colitis, celiac disease); electrolyte abnormality (eg, hyponatremia, hypokalemia, hypocalcemia, hypophosphatemia, refractory potassium depletion); diabetes mellitus; nephrolithiasis; or osteoporosis
243 mg elemental Mg provides ~60% of recommended daily intake (RDI)
RDI for adults is 400 mg/day
Other ingredients: Xylitol, citric acid, natural and artificial orange flavor, dextrin, sucralose
Administration
Mix with 4-8 oz of water, stir well and drink
May take with or without food
Store in a dry location at 59-86°F (15-30°C)
Pediatric dosage forms and strengths
Safety and efficacy not established
Magnitria (trimagnesium citrate anhydrous) adverse (side) effects
Frequency not defined
Asthenia
Dizziness
Hypotension
Respiratory depression
Diarrhea
Abdominal cramping
Electrolyte imbalance
Hypermagnesemia
Muscle weakness
Warnings
Contraindications
Known hypersensitivity to proton pump inhibitors
GI obstructions
Hypermagnesemia
Cautions
Kidney dysfunction
Patients who experience a sudden change in bowel habits
Coadministration with calcium channel blockers; magnesium may enhance the hypotensive effect of the calcium channel blockers
May enhance neuromuscular-blocking effect of neuromuscular-blocking agents
Avoid concomitant use of calcium polystyrene sulfonate
High fat content of food decreases magnesium absorption
Pregnancy and lactation
Pregnancy category: B; crosses placenta, physician should guide dosage for pregnant women
Lactation: Excreted in human breast milk; concentrations remain constant during the first year of lactation; effects of prolonged increments in magnesium are not known
Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Magnitria (trimagnesium citrate anhydrous)
Mechanism of action
Plays an important role in more than 300 biochemical reactions in the body, participating in neuromuscular activity, excitation-contraction coupling, temperature regulation, detoxification reactions, synthetic processes (including DNA and RNA synthesis), and energy production through carbohydrate metabolism
Absorption
At normal intake levels, ionic fractional absorption is 25-50%
Distribution
~50% stored in bone; remaining 50% intracellular
~1% of total body magnesium is in plasma (55-70% ionized, 20-30% protein bound, 5-15% complexed with anions)
Elimination
Excretion: Principally in urine
